Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events
Sicherheit und Wirksamkeit der erneuten Behandlung mit Immun-Checkpoint-Inhibitoren nach schweren immunvermittelten Nebenwirkungen
The Oncologist · 04.06.2025 · 30 (6)
DOI: 10.1093/oncolo/oyaf120 ↗Auf einen Blick
Bei 1271 Krebspatient:innen unter ICIs traten schwere irAEs bei 17,5 % auf. Nach erneuter Behandlung kam es bei 30,4 % zu rezidivierenden oder neuen irAEs Grad ≥2; die Ansprechrate lag bei 28,3 %.
Fragestellung
Wie sicher und wirksam ist eine erneute Behandlung mit ICIs nach schweren immunvermittelten Nebenwirkungen?
Methode
Retrospektive Analyse von 1271 Patient:innen mit Malignomen an einem Universitätsklinikum in Japan; Beobachtung von September 2014 bis Juni 2023.
Ergebnisse
Schwere irAEs Grad ≥3 traten bei 222 Patient:innen (17,5 %) auf. 46 von 162 Patient:innen erhielten ein Retreatment. 14 (30,4 %) hatten rezidivierende oder neue irAEs Grad ≥2; ORR 28,3 % (13/46).
Schlussfolgerung der Autor:innen
Die erneute Behandlung mit ICIs zeigte ein beherrschbares Sicherheitsprofil und vielversprechende Wirksamkeit, auch bei irAEs Grad ≥3. Sie kann bei begrenzten Alternativen eine Option sein.
Kernaussagen
- Schwere irAEs traten bei 222 von 1271 Patient:innen auf.
- Nach Retreatment: 30,4 % mit rezidivierenden oder neuen irAEs Grad ≥2.
- Objektive Ansprechrate nach Retreatment: 28,3 % (13/46).
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 14.06.2025. Verfasst von Kazuyuki Mizuno und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KAKENHI.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, they can trigger severe immune-related adverse events (irAEs). The safety and efficacy of ICI retreatment after severe irAEs remain poorly understood.
Methods
We conducted a retrospective analysis of 1271 patients with malignancies treated with ICIs at a university hospital in Japan between September 2014 and June 2023. We evaluated the incidence and characteristics of severe irAEs, defined as grade ≥3, and the safety and efficacy of ICI retreatment.
Results
Severe irAEs occurred in 222 patients (17.5%). Patients with single endocrinopathies were excluded, and 46 (28.4%) of the remaining 162 patients underwent ICI retreatment. Upon retreatment, 14 patients (30.4%) experienced recurrent or new grade ≥2 irAEs. One patient who experienced hepatotoxicity (grade 3) at initial ICI treatment developed a recurrence (grade 4). Regarding antitumor response, the objective response rate to retreatment was 28.3% (13/46), with 10.9% achieving complete and 17.4% partial response. The median duration of ICI administration after retreatment was 218 days (95% confidence interval [CI]: 84-399). At 1 year after retreatment, 15.4% (95% CI: 6.8-27.4) of patients discontinued due to irAEs, 44.4% (95% CI: 29.7-58.1) due to disease progression, 6.6% (95% CI: 1.7-16.3) completed planned treatment, and 33.4% (95% CI: 20.3-47.2) continued treatment.
Conclusions
ICI retreatment after severe irAEs demonstrated a manageable safety profile and promising efficacy, even in patients with grade ≥3 irAEs. ICI retreatment may be a viable option for patients with limited alternatives, particularly those showing favorable antitumor responses at initial treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID-Profile: Kazuyuki Mizuno, Takanori Ito, Tomoko Kobayashi, Shintaro Iwama, Tetsunari Hase, Noritoshi Kato, Shoichi Maruyama, Masashi Akiyama, Yuichi Ando
Förderung
- KAKENHI
Zitieren
APA
Mizuno, K., Ito, T., Sawada, T., Kobayashi, T., Iwama, S., Mori, S., Hase, T., Fukami, Y., Furusawa, K., Yura, Y., Morimoto, R., Sajiki, A. F., Ushida, H., Kato, N., Maruyama, S., Murohara, T., Katsuno, M., Ishii, M., Akiyama, M., …, & Ando, Y. (2025). Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf120
Vancouver
Mizuno K, Ito T, Sawada T, Kobayashi T, Iwama S, Mori S, et al. Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf120
BibTeX
@article{Mizuno2025,
author = {Mizuno, Kazuyuki and Ito, Takanori and Sawada, Tsunaki and Kobayashi, Tomoko and Iwama, Shintaro and Mori, Shoichiro and Hase, Tetsunari and Fukami, Yuki and Furusawa, Kenji and Yura, Yoshimitsu and Morimoto, Ryota and Sajiki, Ai Fujita and Ushida, Hiroaki and Kato, Noritoshi and Maruyama, Shoichi and Murohara, Toyoaki and Katsuno, Masahisa and Ishii, Makoto and Akiyama, Masashi and Arima, Hiroshi and Kawashima, Hiroki and Ando, Yuichi},
title = {Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {6},
doi = {10.1093/oncolo/oyaf120}
}
EUVIMED